AR067517A1 - Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos - Google Patents

Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos

Info

Publication number
AR067517A1
AR067517A1 ARP080102991A ARP080102991A AR067517A1 AR 067517 A1 AR067517 A1 AR 067517A1 AR P080102991 A ARP080102991 A AR P080102991A AR P080102991 A ARP080102991 A AR P080102991A AR 067517 A1 AR067517 A1 AR 067517A1
Authority
AR
Argentina
Prior art keywords
receiver
met
dimerization
hepatocites
hgf
Prior art date
Application number
ARP080102991A
Other languages
English (en)
Spanish (es)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067517(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR067517A1 publication Critical patent/AR067517A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
ARP080102991A 2007-07-12 2008-07-11 Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos AR067517A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
US2063908P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
AR067517A1 true AR067517A1 (es) 2009-10-14

Family

ID=38871713

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP080102991A AR067517A1 (es) 2007-07-12 2008-07-11 Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos
ARP170102558A AR109659A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
ARP170102559A AR109660A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
ARP170102560A AR109535A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP170102558A AR109659A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
ARP170102559A AR109660A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
ARP170102560A AR109535A2 (es) 2007-07-12 2017-09-15 Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos

Country Status (35)

Country Link
US (6) US8329173B2 (enExample)
EP (6) EP2014681A1 (enExample)
JP (4) JP5562844B2 (enExample)
KR (4) KR101701686B1 (enExample)
CN (4) CN103509113B (enExample)
AR (4) AR067517A1 (enExample)
AU (1) AU2008274171B2 (enExample)
BR (1) BRPI0815564B8 (enExample)
CA (4) CA2888691C (enExample)
CL (1) CL2008002015A1 (enExample)
CO (1) CO6170364A2 (enExample)
CY (1) CY1116608T1 (enExample)
DK (1) DK2188312T3 (enExample)
ES (5) ES2686693T3 (enExample)
HR (1) HRP20150887T1 (enExample)
HU (1) HUE026026T2 (enExample)
IL (5) IL203114A (enExample)
MA (1) MA31977B1 (enExample)
ME (1) ME02341B (enExample)
MX (3) MX345391B (enExample)
MY (1) MY158756A (enExample)
NZ (4) NZ613716A (enExample)
PA (1) PA8789201A1 (enExample)
PH (3) PH12018502039A1 (enExample)
PL (1) PL2188312T3 (enExample)
PT (1) PT2188312E (enExample)
RS (1) RS54197B1 (enExample)
RU (1) RU2552161C2 (enExample)
SA (1) SA08290423B1 (enExample)
SG (1) SG183015A1 (enExample)
SI (1) SI2188312T1 (enExample)
TN (1) TN2010000016A1 (enExample)
TW (4) TWI602830B (enExample)
WO (1) WO2009007427A2 (enExample)
ZA (1) ZA201000966B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
RS66008B1 (sr) * 2010-03-10 2024-10-31 Genmab As Monoklonska antitela protiv c-met
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3264089A1 (en) 2010-08-31 2018-01-03 Genentech, Inc. Biomarkers and methods of treatment
SG188324A1 (en) 2010-09-03 2013-04-30 Academia Sinica Anti-c-met antibody and methods of use thereof
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2011325098B2 (en) 2010-11-03 2016-07-14 Argen-X N.V. c-Met antibody combinations
CN103459422A (zh) 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
KR101444837B1 (ko) * 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
NZ780183A (en) 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2012275233A1 (en) * 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
AU2012340826A1 (en) 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013192594A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
WO2016079194A1 (en) * 2014-11-20 2016-05-26 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
ES3029413T3 (en) 2015-04-02 2025-06-24 Ablynx Nv Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
WO2017062496A2 (en) * 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
US11235063B2 (en) 2015-11-03 2022-02-01 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
KR20230028574A (ko) 2016-05-17 2023-02-28 애브비 바이오테라퓨틱스 인크. 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
CA3029977A1 (en) * 2016-07-06 2018-01-11 Celgene Corporation Antibodies with low immunogenicity and uses thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
US11525004B2 (en) 2017-07-20 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Recombinant CD123-binding antibodies
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
SMT202500038T1 (it) * 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR20210137485A (ko) 2019-04-05 2021-11-17 아카데미아 시니카 시알리다제-내성 당류 및 이의 제조 및 사용 방법
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
IL298035A (en) 2020-05-08 2023-01-01 Academia Sinica Chimeric influenza vaccines
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
WO2022126416A1 (zh) * 2020-12-16 2022-06-23 武汉友芝友生物制药股份有限公司 抗bcma抗体及其制备方法和应用
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
BR112023020562A2 (pt) 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
EP4164687A4 (en) 2021-04-12 2024-08-14 Academia Sinica IMPROVED CORONAVIRUS VACCINE
UY39743A (es) 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023129928A2 (en) * 2021-12-27 2023-07-06 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
IL319558A (en) 2023-04-08 2025-05-01 Rock Biomedical Inc Methods and compositions for targeted delivery using polymersomes
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
NZ543960A (en) * 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
RU2006124743A (ru) * 2003-12-11 2008-01-20 Дженентек, Инк. (Us) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
CA2597265C (en) * 2005-02-10 2015-03-24 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
CA2854576A1 (en) 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
EP1913027B1 (en) 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
KR101429297B1 (ko) 2006-02-06 2014-08-12 메테레시스 트랜스레이셔날 리서치 에스.에이. 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)

Also Published As

Publication number Publication date
KR101719084B1 (ko) 2017-03-22
PH12018502039A1 (en) 2019-08-19
IL223106B (en) 2020-06-30
JP2014113155A (ja) 2014-06-26
SI2188312T1 (sl) 2015-09-30
EP2535356A1 (en) 2012-12-19
CA2982484A1 (en) 2009-01-15
RS54197B1 (sr) 2015-12-31
JP5889923B2 (ja) 2016-03-22
PT2188312E (pt) 2015-10-05
AR109659A2 (es) 2019-01-09
BRPI0815564B1 (pt) 2020-01-21
CN103509113B (zh) 2015-10-21
TW200911828A (en) 2009-03-16
US9107907B2 (en) 2015-08-18
CN101981054A (zh) 2011-02-23
TN2010000016A1 (en) 2011-09-26
JP2014113154A (ja) 2014-06-26
EP2535356B1 (en) 2018-06-13
JP2010532982A (ja) 2010-10-21
KR101701686B1 (ko) 2017-02-01
CA2694418C (en) 2018-03-27
AR109660A2 (es) 2019-01-09
CO6170364A2 (es) 2010-06-18
NZ583041A (en) 2012-06-29
KR20160019974A (ko) 2016-02-22
MX345391B (es) 2017-01-27
PH12018502040A1 (en) 2019-08-19
US20130273060A1 (en) 2013-10-17
WO2009007427A2 (en) 2009-01-15
US8329173B2 (en) 2012-12-11
IL223108A0 (en) 2012-12-31
US8871910B2 (en) 2014-10-28
HRP20150887T1 (hr) 2015-09-25
IL223106A0 (en) 2012-12-31
US20140010818A1 (en) 2014-01-09
EP2188312B1 (en) 2015-05-27
CA2888691C (en) 2023-01-03
US20100115639A1 (en) 2010-05-06
ES2693542T3 (es) 2018-12-12
CL2008002015A1 (es) 2008-11-21
KR20150070451A (ko) 2015-06-24
BRPI0815564B8 (pt) 2021-05-25
KR20100044212A (ko) 2010-04-29
US8871909B2 (en) 2014-10-28
HK1149024A1 (en) 2011-09-23
US20130272957A1 (en) 2013-10-17
EP2415785A1 (en) 2012-02-08
CY1116608T1 (el) 2017-03-15
HK1193620A1 (zh) 2014-09-26
JP5562844B2 (ja) 2014-07-30
RU2552161C2 (ru) 2015-06-10
BRPI0815564A2 (pt) 2015-02-18
MA31977B1 (fr) 2011-01-03
EP2535357B1 (en) 2018-08-08
PL2188312T3 (pl) 2016-01-29
CN103509112A (zh) 2014-01-15
CN103183739A (zh) 2013-07-03
US20130280257A1 (en) 2013-10-24
ES2686693T3 (es) 2018-10-19
US20150252114A1 (en) 2015-09-10
US8889832B2 (en) 2014-11-18
TWI602830B (zh) 2017-10-21
IL223105B (en) 2020-02-27
AU2008274171B2 (en) 2014-02-27
EP2415784A1 (en) 2012-02-08
TWI602829B (zh) 2017-10-21
HK1193619A1 (zh) 2014-09-26
HUE026026T2 (en) 2016-05-30
CN103509112B (zh) 2015-10-21
CA2981821A1 (en) 2009-01-15
CN103509113A (zh) 2014-01-15
KR101625234B1 (ko) 2016-05-30
IL223109B (en) 2019-06-30
CA2694418A1 (en) 2009-01-15
TW201605891A (zh) 2016-02-16
DK2188312T3 (en) 2015-08-03
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
MX353449B (es) 2018-01-08
NZ613716A (en) 2015-01-30
IL223105A0 (en) 2012-12-31
EP2415784B1 (en) 2018-06-13
IL203114A (en) 2015-03-31
SA08290423B1 (ar) 2013-12-23
JP5889924B2 (ja) 2016-03-22
SG183015A1 (en) 2012-08-30
JP5889925B2 (ja) 2016-03-22
JP2014113153A (ja) 2014-06-26
EP2415785B1 (en) 2018-04-25
ME02341B (me) 2015-12-31
CN103183739B (zh) 2016-08-17
NZ599958A (en) 2013-11-29
TW201437231A (zh) 2014-10-01
KR101701685B1 (ko) 2017-02-01
RU2010104633A (ru) 2011-08-20
TWI592427B (zh) 2017-07-21
PH12018502038A1 (en) 2019-08-19
MY158756A (en) 2016-11-15
MX341012B (es) 2016-08-03
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
ZA201000966B (en) 2011-02-23
CA2981821C (en) 2020-07-28
WO2009007427A3 (en) 2009-04-09
AU2008274171A1 (en) 2009-01-15
AR109535A2 (es) 2018-12-19
EP2014681A1 (en) 2009-01-14
CA2888691A1 (en) 2009-01-15
IL223108B (en) 2019-06-30
IL223109A0 (en) 2012-12-31
CN101981054B (zh) 2015-04-15
TW201605892A (zh) 2016-02-16
TWI549965B (zh) 2016-09-21
PA8789201A1 (es) 2009-08-26
ES2678495T3 (es) 2018-08-13
EP2535357A1 (en) 2012-12-19
CA2982484C (en) 2021-06-01
EP2188312A2 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
AR067517A1 (es) Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos
AR113211A2 (es) Derivados de bencilfenilciclohexano y métodos de uso
CR20110509A (es) Composicion farmaceutica
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
PA8740901A1 (es) Compuestos organicos
MX2012003413A (es) Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2008003083A1 (es) Uso de un beta bloqueador seleccionado de un beta bloqueador no selectivo y/o un beta bloqueador selectivo beta-1 para preparar un medicamento util para el tratamiento de los hemangiomas.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT201100017A (es) Derivados de piridazina como inhibidores de smo
AR089252A1 (es) Conjugados de principio activo-ligante (adc) y su uso
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
AR089083A1 (es) Anticuerpos para receptor de factor de crecimiento epidermico 3 (her3)
BR112012030805A2 (pt) anticorpo anti-cmet
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
UY32426A (es) Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX339644B (es) Sales de xantilio 3,6-disustituidas.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.

Legal Events

Date Code Title Description
FG Grant, registration